NCT06795178 2025-04-27
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
Clinical Trials
14 trialsNCT06795191 2025-04-27
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT05771896 2023-09-14
CARE
GenesisCare USA
Phase 3 Withdrawn
NCT05098327 2023-08-15
Pioglitazone and Insulin Resistance in ADT
State University of New York at Buffalo
Phase 3 Withdrawn
NCT04225299 2020-11-13
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Steba Biotech S.A.
Phase 3 Withdrawn
NCT03488810 2020-08-17
ARN-509
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Withdrawn
NCT02053311 2018-07-30
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Swiss Cancer Institute
Phase 3 Withdrawn
NCT00691899 2016-08-12
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT00041171 2016-07-12
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Withdrawn
NCT02260349 2016-03-10
Interest of Indocyanine Green in Neoplastic Prostatic Tissue
Centre Hospitalier Universitaire de Saint Etienne
Phase 3 Withdrawn
NCT01214291 2013-11-15
TREAT2
GTx
Phase 3 Withdrawn
NCT00043212 2013-05-01
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
Northwest Biotherapeutics
Phase 3 Withdrawn
NCT00258466 2013-04-08
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 3 Withdrawn
NCT00728533 2011-03-18
Open-Label, Randomised Parallel-Group Study
Ferring Pharmaceuticals
Phase 3 Withdrawn